OR WAIT null SECS
August 15, 2024
Article
Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
August 14, 2024
Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.
August 12, 2024
Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.
August 11, 2024
Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.
August 09, 2024
Interim analysis of STELLAR showed health-related quality of life domains were within a normal range after hematopoietic cell transplant for SCD.
August 08, 2024
Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.
August 07, 2024
Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.
August 06, 2024
Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.
Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.
August 05, 2024
Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.